



General Assembly

Amendment

January Session, 2021

LCO No. 9650



Offered by:

REP. REBIMBAS, 70th Dist.

REP. FISHBEIN, 90th Dist.

To: Subst. Senate Bill No. 262

File No. 12

Cal. No. 554

**"AN ACT REQUIRING MANUFACTURERS OF BRAND NAME
PRESCRIPTION DRUGS TO PROVIDE SAMPLES OF SUCH DRUGS
TO MANUFACTURERS OF GENERIC PRESCRIPTION DRUGS."**

1 Strike everything after the enacting clause and substitute the
2 following in lieu thereof:

3 "Section 1. (*Effective from passage*) The Department of Consumer
4 Protection shall study the efficacy of the federal Creating and Restoring
5 Equal Access to Equivalent Samples Act of 2019, incorporated into the
6 Further Consolidated Appropriations Act, 2020, P.L. 116-94, on
7 lowering prescription drug costs and encouraging generic competition
8 in the pharmaceutical market of the state and make recommendations
9 for legislative changes that would not be preempted by federal law. Not
10 later than February 1, 2022, the department shall submit a report, in
11 accordance with the provisions of section 11-4a of the general statutes,
12 to the joint standing committee of the General Assembly having
13 cognizance of matters relating to general law, containing any findings
14 of the study and such recommendations."

This act shall take effect as follows and shall amend the following sections:		
---	--	--

Section 1	<i>from passage</i>	New section
-----------	---------------------	-------------